Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401247 | 0.89 | ALDH1A1 (0.58) | ALDH1A1LMNAKDM4EAPOBEC3AAPOBEC3G | |
| SCHEMBL8070812 | 0.86 | ALDH1A1 (0.75) | ALDH1A1LMNAKDM4EAPOBEC3AAPOBEC3G | |
| SCHEMBL7793171 | 0.86 | ALDH1A1 (0.61) | ALDH1A1LMNAKDM4EAPOBEC3AAPOBEC3G | |
| SCHEMBL6353084 | 0.86 | ALDH1A1 (0.61) | ALDH1A1LMNAKDM4EAPOBEC3AAPOBEC3G | |
| SCHEMBL9861200 | 0.83 | ALDH1A1 (0.58) | ALDH1A1LMNAKDM4EAPOBEC3AAPOBEC3G | |
| SCHEMBL15829156 | 0.83 | ALDH1A1 (0.58) | ALDH1A1LMNAKDM4EAPOBEC3AAPOBEC3G | |
| SCHEMBL526338 | 0.81 | ALDH1A1 (0.69) | ALDH1A1LMNAKDM4EAPOBEC3AAPOBEC3G | |
| SCHEMBL13990828 | 0.81 | ALDH1A1 (0.69) | ALDH1A1LMNAKDM4EAPOBEC3AAPOBEC3G | |
| SCHEMBL12715390 | 0.81 | ALDH1A1 (0.69) | ALDH1A1LMNAKDM4EAPOBEC3AAPOBEC3G | |
| SCHEMBL28140415 | 0.81 | ALDH1A1 (0.69) | ALDH1A1LMNAKDM4EAPOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230103337-A1 | MEDICINE FOR IMPROVING STATE OF PREGNANCY, AND USE THEREOF | Yamaguchi, Koushi (JP) | 2023-04-06 | — | — | US | disclosed |
| US-11541040-B2 | Medicine for improving state of pregnancy, and use thereof | Yamaguchi, Kouchi (JP) | 2023-01-03 | — | — | US | disclosed |
| EP-3977995-A1 | TACROLIMUS FOR AMELIORATING PREGNANCY CONDITIONS | Yamaguchi, Koushi (JP) | 2022-04-06 | — | — | EP | disclosed |
| EP-3900729-A1 | AGENT FOR IMPROVING INFERTILITY, RECURRENT MISCARRIAGE, AND STATE OF PREGNANCY | Yamaguchi, Koushi (JP) | 2021-10-27 | — | — | EP | disclosed |
| EP-3246036-B1 | MEDICINE FOR IMPROVING PREGNANCY-INDUCED HYPERTENSION SYNDROME | YAMAGUCHI KOUSHI (JP) | 2021-10-13 | — | — | EP | disclosed |
| CN-113226331-A | Medicine for improving infertility or pregnancy state | 山口晃史 | 2021-08-06 | — | — | CN | disclosed |
| US-20210228551-A1 | THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN MATERNOFETAL RELATIONSHIP | YAMAGUCHI KOUSHI (JP) | 2021-07-29 | — | — | US | disclosed |
| EP-3834826-A1 | THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN MATERNO-FETAL RELATIONSHIP | Yamaguchi, Koushi (JP) | 2021-06-16 | — | — | EP | disclosed |
| CN-112533599-A | Therapeutic agent for humoral immunity-related diseases in maternal-fetal relationship | 山口晃史 | 2021-03-19 | — | — | CN | disclosed |
| CN-107106588-B | Agent for improving pregnancy status and use thereof | 山口晃史 | 2020-08-11 | — | — | CN | disclosed |
| EP-0483842-A1 | Pharmaceutical compositions containing tricyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-05-06 | — | — | EP | disclosed |
| US-5110811-A | Antibody inhibitors | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-05-05 | — | — | US | disclosed |
| WO-1992000313-A1 | TRICYCLO COMPOUNDS, A PROCESS FOR THEIR PRODUCTION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-01-09 | — | — | WO | disclosed |
| WO-1991019495-A1 | USE OF A MACROLIDE COMPOUND SUCH AS FK 506 FOR MANUFACTURING A MEDICAMENT FOR TREATING IDIOPATHIC THROMBOCYTOPENIC PURPURA AND BASEDOW'S DISEASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-12-26 | — | — | WO | disclosed |
| WO-1991017754-A1 | METHODS FOR TREATING AND PREVENTING INFLAMMATION OF MUCOSA AND BLOOD VESSELS USING FK 506 AND RELATED COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-28 | — | — | WO | disclosed |
| EP-0444659-A2 | A pharmaceutical solution comprising derivatives of FK506 | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-09-04 | — | — | EP | disclosed |
| US-4956352-A | TREATING AUTOIMMUNE DISEASES, RESISTANCE TO TRANSPLANTATION, INFECTIONS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-09-11 | — | — | US | disclosed |
| US-4929611-A | ANTIBODY INHIBITORS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-05-29 | — | — | US | disclosed |
| US-4894366-A | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-01-16 | — | — | US | disclosed |
| EP-0184162-A2 | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103337-A1 | MEDICINE FOR IMPROVING STATE OF PREGNANCY, AND USE THEREOF | PGF, SLC10A1, SLC26A4 | ALDH1A1 706/4885LMNA 2424/4885KDM4E 4290/4885 |
| US-11541040-B2 | Medicine for improving state of pregnancy, and use thereof | PGF, SLC10A1, SLC26A4 | ALDH1A1 551/4885LMNA 2875/4885KDM4E 4161/4885 |
| US-20210228551-A1 | THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN MATERNOFETAL RELATIONSHIP | PGF, HAMP, HLA-DRB1 | ALDH1A1 2911/4885LMNA 4138/4885KDM4E 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.